NCT04359901View on ClinicalTrials.gov

Sarilumab for Patients With Moderate COVID-19 Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 10, 2020

Primary Completion Date

August 2, 2021

Study Completion Date

August 2, 2021

Conditions
COVID
Interventions
BIOLOGICAL

SARILUMAB

Single dose of 400 mg subcutaneous sarilumab

Trial Locations (5)

06516

VA Connecticut Healthcare System, West Haven

04330

VA Maine Healthcare System, Augusta

02132

VA Boston Healthcare System, Boston

02908

Providence VA Medical Center, Providence

05009

VA Medical Center - White River Junction, White River Junction

All Listed Sponsors
lead

Westyn Branch-Elliman

FED

NCT04359901 - Sarilumab for Patients With Moderate COVID-19 Disease | Biotech Hunter | Biotech Hunter